The Food and Drug Administration approved daratumumab (Darzalex) plus lenalidomide and dexamethasone (Rd) for the treatment of patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplant (ASCT), according to Janssen, the manufacturer of the drug.
With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.
The Food and Drug Administration lifted a partial clinical hold on the CANOVA trial, examining venetoclax with dexamethasone in relapsed/refractory myeloma.
While clinical trials drive FDA approvals, real-world data may be equally important as it lends insight to a broader group of patients.
The FDA has granted a priority review designation to a supplemental biologics license application for niraparib (Zejula) for the treatment of patients with advanced ovarian cancer.
The FDA has granted an approval to a prefilled syringe for lanreotide (Somatuline Depot), which has been designed to enable healthcare providers to administer the injection easier, for the treatment of adults with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors.
Pancreatic cancer mortality is on the rise compared with other gastrointestinal malignancies, spurring an abundance of novel treatment approaches to combat the disease.
Personalized treatments are drastically improving the outcomes of patients with non-small cell lung cancer, but there is still work to be done when it comes to understanding drug resistance.
Biosimilars continue to push their way into the oncology market. They're different from generic drugs. Here's what nurses should know.
Oncology nurses shouldn’t be concerned if patients with non-small cell lung cancer experience skin toxic effects after immunotherapy.
The FDA approved pembrolizumab (Keytruda) for patients with advanced small cell lung cancer (SCLC) who experienced disease progression after 2 or more prior lines of therapy.
Oncology nursing is more than just a job to Barbara Bittner, RN, OCN.
The Food and Drug Administration (FDA) approved trastuzumab-anns (Kajinti), a biosimilar of trastuzumab (Herceptin) for the treatment of HER2-overexpressing breast cancer, metastatic gastric or gastroesophageal junction adenocarcinoma.
The FDA approved pembrolizumab alone or in combination with 5-FU to treat recurrent or metastatic head and neck squamous cell carcinoma.
The FDA has granted an accelerated approval to polatuzumab vedotin (Polivy) for use in combination with bendamustine and rituximab (Rituxan; BR) for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who have received at least 2 prior therapies.
The FDA granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.
Here are the top 5 Oncology Nursing News stories for May 2019.
Monoclonal antibodies, proteasome inhibitors, and targeted agents are among the many options in the crowded treatment landscape of relapsed/refractory multiple myeloma, and the emergence of drugs, such as venetoclax (Venclexta) and selinexor, could add to the complexity of this paradigm, said Cristina Gasparetto, MD.
Studies have shown that heated chemotherapy may benefit women with ovarian cancer, but is this the right treatment for everyone? One expert weighs in.
The FDA granted a priority review to daratumumab (Darzalex) in combination with bortezomib (Velcade), thalidomide and dexamethasone (Vtd) for the front-line treatment of newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant.
The results of genetic testing could have major implications for patients with breast cancer and their families.
Healthcare providers should not base cancer care with immune checkpoint inhibitors on gender, according to recent study findings.
Trebek's current outcome could offer a source of hope for patients with pancreatic cancer, who typically have poor prognoses.
The FDA has approved the R2 regimen of lenalidomide (Revlimid) plus rituximab (Rituxan) for use in patients with previously treated follicular lymphoma and marginal zone lymphoma (MZL).
In non–small cell lung cancer (NSCLC), KRAS G12 mutations have been historically difficult to target, and research efforts dedicated to the development of effective targeted therapies for NRG1 fusions have not been successful. However, several biopharmaceutical companies are in the early stages of addressing that challenge, explained Sai-Hong I. Ou, MD, PhD.
Genetic and genomic testing are becoming more popular and useful in the cancer space.
There may be a correlation between androgen deprivation therapy and cardiac complications, but more research is still needed.
The FDA has approved the PI3K inhibitor alpelisib (Piqray) for the treatment of postmenopausal women, and men, with HR-positive, HER2-negative, PIK3CA-mutated, advanced or metastatic breast cancer following progression on or after an endocrine-based regimen.
The Food and Drug Administration (FDA) approved ruxolitinib (Jakafi) for the treatment of patients 12 years or older with steroid-refractory acute graft-versus-host disease.